These three small-cap stocks have outstanding growth potential.
News & Analysis: Regenxbio
RGNX earnings call for the period ending December 31, 2018.
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.
A small biotech is on the cusp of a big market opportunity.
This gene therapy company has big catalysts approaching that could cause shares to pop or drop.
These gene therapy stocks have generated huge returns so far this year. But can they keep up their winning ways?
On a day the market benchmarks closed up, Novartis announced it's buying AveXis and Leucadia National detailed plans to divest some assets and rename itself.
The biopharma darling provided a year-end 2017 corporate update. Wall Street wasn't impressed.